Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 4th February 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Equine inhaler receives marketing authorisation
"Treating severe equine asthma can be challenging for veterinarians and horse owners" - Erich Schoett.

Aservo Equihaler® will be available for EU distribution in 2020

A novel equine inhaler set to benefit horses suffering from severe equine asthma has been granted marketing approval by the European Commission.


Marking an industry-first in equine medicine, the Aservo Equihaler® is the culmination of more than a decade of collaboration between Boehringer Ingelheim’s human pharma and animal health R&D groups. It is expected to be available for veterinary surgeons in the EU in 2020.


The inhaler incorporates a unique Soft Mist Technology®, found in the human Respimat® inhaler. This allows the active ingredient - ciclesonide - to be inhaled deep into the lung, thereby reducing the risk of lower airway inflammation.

Designed specifically for horses, the inhaler also features an ergonomic handle, dosing lever for ease of handling and a nostril adaptor that fits inside the nostril of the horse to allow for easy inhalation.

Erich Schoett, global business head of equine for the Boehringer Ingelheim Animal Health Business Unit, said: “Treating severe equine asthma can be challenging for veterinarians and horse owners, who struggle to find safe and effective ways to help horses breathe.


“Bringing a new, safe and effective treatment to the market is something that we can really be proud of. It is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.”

Become a member or log in to add this story to your CPD history

Cold-water dip to raise funds for Vetlife

News Story 1
 The veterinary mental health charity Vetlife is inviting the veterinary community to join it for a sponsored cold-water dip.

The event will take place at Walpole Bay, Margate, on 17 May during Mental Health Awareness Week. Participants of all abilities can join in the challenge and are advised to bring a towel, a hot drink, a snack, and warm clothes to get changed into afterwards.

Those taking part are being asked to try to raise 100 each to support the work of the charity.

Details about how to take part can be found here. 

Click here for more...
News Shorts
Bluetongue low vector period ends

In an update to its bluetongue guidance, the Department for Environment, Food and Rural Affairs (Defra) has announced that the seasonal low vector period for the disease has ended.

With winter over, Defra is planning for a possible increase in cases as midges become more active. It has warned that farms along the east coast of England from Norfolk to Kent, and along the south coast from Kent to Devon, are at highest risk from infected midges blown over from northern Europe.

Since the virus was detected in England in November 2023, there have been 126 confirmed cases. The most recent case to be confirmed was on 1 March 2024.

Farmers are asked to continue to frequently monitor their livestock and ensure their animals and land are registered with the Animal and Plant Health Agency.